Novel Subcutaneous Biologics Show Promise in AD : vimarsana.

Patients with moderate to severe atopic dermatitis could soon have more therapeutic options, with monoclonal antibodies targeting novel immune pathways that reduce disease severity, suggest two trials.

Related Keywords

Germany , Oregon , United States , Amsterdam , Noord Holland , Netherlands , Portland , Eric Simpson , Stephan Weidinger , Tiagor Matos , Department Of Dermatology , European Academy Of Dermatology , Kymab Ltd , University Hospital Schleswig Holstein , Amsterdam University Medical Centers , Oregon Health Science University , European Academy , Eczema Area , Severity Index , Oregon Health , Science University , Medscape Medical News , Validated Investigator Global Assessment , Atopic Dermatitis , Body Surface Area , Peak Pruritus Numerical Rating Scale , Dermatitis , Biologic Therapy , Monoclonal Antibody , Etuximab , Ituximab , Conjunctivitis , Corneal Disease , Allergy , Cytokines , Receptors , Antigens , Eczema , Europe , European , Hospitals , Interleukins , Preventive Screening , Screening , Pruritus , Pruritis , Pitch , Severity Indices ,